Opus’ LYNX-2 Phase III Trial Hits Primary Endpoint for Post-LASIK Night Vision Treatment
Opus’ phentolamine eye drops hit the LYNX-2 letter-gain target on mesopic low contrast distance visual acuity. Opus Genetics (North Carolina,…
Iolyx Therapeutics Announces Promising Phase II Results for ILYX-002 in Autoimmune Dry Eye Disease
ILYX-002 shows 3x greater corneal healing effect compared to current therapies on the market. Iolyx Therapeutics (California, United States), a…
popular posts
latest posts
